Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
Carlo Visco, Luigi Marcheselli, Roberto Mina, et al.
Blood Advances (2021) Vol. 6, Iss. 1, pp. 327-338
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
Tanaya Shree, Vishnu Shankar, Julian J.K. Lohmeyer, et al.
Blood Cancer Discovery (2022) Vol. 3, Iss. 2, pp. 95-102
Open Access | Times Cited: 41
The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody
Shuhei Maruyama, Daiki Wada, Shuji Kanayama, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma
Dan Liu, Yin Xia, Hui Wang, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations
Francesco Passamonti, Emanuele Nicastri, Alice Di Rocco, et al.
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 3-15
Open Access | Times Cited: 18
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial
Alessandro Pulsoni, Simone Ferrero, Maria Elena Tosti, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 7, pp. e499-e509
Closed Access | Times Cited: 3
COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response
Ivan Gur, Amir Giladi, Yonathan Nachum Isenberg, et al.
Acta Haematologica (2022) Vol. 145, Iss. 3, pp. 297-309
Open Access | Times Cited: 15
Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases
Igor Aurer, Ozren Jakšić, Sandra Bašić‐Kinda, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 331-331
Open Access | Times Cited: 2
Management of vaccinations in patients with non‐Hodgkin lymphoma
Michele Merli, Andrea Costantini, Silvio Tafuri, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 5, pp. 1617-1634
Open Access | Times Cited: 2
Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival – a Swedish Lymphoma Register Study
Sara Ekberg, Daniel Molin, Simon Pahnke, et al.
Acta Oncologica (2024) Vol. 63, pp. 164-168
Open Access | Times Cited: 2
Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights
Heng Joo Ng, Maaz Kamal Alata, Quang The Nguyen, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Impact of Hypogammaglobulinemia on the Course of COVID-19 in a Non-Intensive Care Setting: A Single-Center Retrospective Cohort Study
Riccardo Scarpa, Alessandro Dell’Edera, Carla Felice, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 13
Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitant hematological malignancies: An Italian retrospective study
Francesco Lanza, Federica Monaco, Fabio Ciceri, et al.
Hematological Oncology (2022) Vol. 40, Iss. 5, pp. 857-863
Open Access | Times Cited: 13
SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort
Michele Merli, Isacco Ferrarini, Francesco Merli, et al.
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 128-138
Open Access | Times Cited: 12
COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic
Iwona Hus, Agnieszka Szymczyk, Joanna Mańko, et al.
Biology (2023) Vol. 12, Iss. 4, pp. 545-545
Open Access | Times Cited: 6
Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry
Marie‐Kristin Tilch, Carlo Visco, Sandra Bašić‐Kinda, et al.
HemaSphere (2022) Vol. 6, Iss. 5, pp. e0711-e0711
Open Access | Times Cited: 10
Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak
Milena Kohn, Tamim Alsuliman, Sylvain Lamure, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2022) Vol. 63, Iss. 11, pp. 2686-2690
Open Access | Times Cited: 10
An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells Committee editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for coronavirus disease-19: time for a global registry
Daniel J. Weiss, Anthony J. Filiano, Jacques Galipeau, et al.
Cytotherapy (2022) Vol. 24, Iss. 11, pp. 1071-1073
Open Access | Times Cited: 10
Predictors of clinical evolution of SARS‐CoV‐2 infection in hematological patients: A systematic review and meta‐analysis
Elena Carrara, Elisa Razzaboni, Anna Maria Azzini, et al.
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 16-25
Open Access | Times Cited: 10
IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients
Huan Xie, Jing Zhang, Ran B. Luo, et al.
BMC Immunology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
B-cell malignancies and COVID-19: a narrative review
David Luque-Paz, Pierre Sesques, Florent Wallet, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 3, pp. 332-337
Open Access | Times Cited: 8
Impact of anti‐SARS‐CoV‐2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study
Giovanni Manfredi Assanto, Alice Di Rocco, Francesco Malfona, et al.
Hematological Oncology (2022) Vol. 41, Iss. 3, pp. 343-353
Open Access | Times Cited: 8
Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic
Esther K. Elliott, Robert Hensen, Larisa M. Haupt, et al.
European Journal Of Haematology (2023) Vol. 110, Iss. 5, pp. 457-469
Open Access | Times Cited: 4
Cancer, more than a “COVID-19 co-morbidity”
Chinmay Jani, Robert T. Schooley, Rana R. McKay, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study
Tamar Berger, Tzippy Shochat, Shlomzion Aumann, et al.
Annals of Hematology (2023) Vol. 102, Iss. 8, pp. 2127-2136
Closed Access | Times Cited: 4
Immune response to COVID‐19 vaccination in patients with Waldenström macroglobulinaemia who pause their BTKi therapy
Katherine Rankin, Priyanka Hastak, Alexander Wong, et al.
eJHaem (2023) Vol. 4, Iss. 3, pp. 728-732
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top